期刊文献+

“良性淋巴瘤”概念的提出及其存在的可能性 被引量:4

Presentation of the concept of “benign lymphoma” and the discussion of the possibility of its existence
原文传递
导出
摘要 淋巴瘤是一种来源于淋巴造血系统的肿瘤,按照以往的观点,淋巴瘤是一种单克隆增生的淋巴组织恶性肿瘤,没有"良性淋巴瘤"概念。近年来在淋巴瘤临床诊治实践中新发现一些生物学行为偏良性的单克隆增生淋巴组织病变,病变恶性潜能极其有限,几乎无进展,对传统淋巴瘤概念和诊断标准形成了一个挑战,也产生了一些疑问和困惑。基于此,作者在国内首次提出了"良性淋巴瘤"的观点并探讨其存在的可能性,期望以此引发专家们对淋巴瘤生物学本质问题的共同探讨和思考。 Lymphoma is a kind of tumor that comes from lymphatic hematopoietic.According to the previous points of views,lymphoma is a kind of malignant tumor which proliferates monoclonally.The concept of "benign lymphoma" does not exist at present.In the clinical practice of recent years,we have found that some monoclonal lymphoid tissue lesions show benign biological behavior and their malignant potential is extremely limited and almost does not develop,so it presents a challenge to the concept of lymphoma and its diagnostic standard.Based on this,the author proposes the concept of "benign lymphoma" here for the first time in China,and discusses the possibility of its existence,so as to trigger the discussion on the biological essence of lymphoma.
作者 李文生
出处 《山东大学学报(医学版)》 CAS 北大核心 2017年第3期1-5,共5页 Journal of Shandong University:Health Sciences
基金 陕西省科技攻关课题(2010K12-02) 陕西省卫生计生科研基金(2016D035)
关键词 淋巴瘤 良性淋巴瘤 克隆性 生物学本质 Lymphoma Benign lymphoma Clonality Biological essence
  • 相关文献

参考文献6

二级参考文献49

  • 1刘迎,武淑兰,薛海鹏,朱平.检测IgH和TCRγ基因重排对NHL分期参考价值的探讨[J].临床肿瘤学杂志,1998,3(1):4-7. 被引量:4
  • 2钟梅,吕亚莉,赵坡,李向红.异源双链鉴定法检测淋巴瘤IgH、TCR-β基因重排[J].诊断病理学杂志,2004,11(4):255-256. 被引量:6
  • 3TIACCI E, TRIFONOV V, SCHIAVONI G, et al. BRAF mutations in hairy-cell leukemia [ J ] . N Engl J Med, 2011, 16, 364(24): 2305-2315. 被引量:1
  • 4TREON S P, XU L, YANG G, et al. MYD88 L265P somatic mutation in WaldenstrSm's macroglobulinemia [ J ] . N Engl J Med, 2012, 367(9): 826-833. 被引量:1
  • 5OTT G, ZIEPERT M, KLAPPER W, et al. Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial in the DSHNHL [ J ] . Blood, 2010, 116(23): 4916-4925. 被引量:1
  • 6MEYER P N, FU K, GREINER T C, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab [ J ] . J Clin Oncol, 2011, 29(2): 200-207. 被引量:1
  • 7VISCO C, LI Y, XU-MONETTE Z Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab- CHOP Consortium Program Study [ J ] . Leukemia, 2012, 26(9): 2103-2013. 被引量:1
  • 8MONTI S, SAVAGE K J, KUTOK J L, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response [ J ] . Blood, 2005, 105(5): 1851-1861. 被引量:1
  • 9JOHNSON N A, SLACK G W, SAVAGE K L, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [ J ] . J Clin Oncol, 2012, 30(28): 3452-3459. 被引量:1
  • 10GREEN T M, YOUNG K H, VISCO C, et al. Immunohistoehemieal double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyelophosphamide, doxorubicin, vincristine, and prednisone [ J ] . J Clin Oncol 2012, 30(28): 3460-3467. 被引量:1

共引文献498

同被引文献32

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部